Amgen is expanding its activities in China and establishing a joint venture with Zhejiang Beta Pharma Co to sell its colon cancer drug Vectibix, Panitumumab.
http://www.pharmatimes.com/Article/13-05-10/Amgen_sets_up_China_JV_with_Zhejiang_Beta.aspx
Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Panitumumab is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc.
It was approved by the U.S. Food and Drug Administration (FDA) for the first time in September 2006, for “the treatment of EGFR-expressing metastatic colorectal cancer with disease progression” despite prior treatment. Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008 for “the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS”.
Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS…
View original post 37 more words
sitanepali
Med.Chem in Nepal 
Leave a comment